Rekah Pharmaceutical Industry Balance Sheet Health
Financial Health criteria checks 4/6
Rekah Pharmaceutical Industry has a total shareholder equity of ₪169.2M and total debt of ₪94.0M, which brings its debt-to-equity ratio to 55.6%. Its total assets and total liabilities are ₪451.8M and ₪282.7M respectively. Rekah Pharmaceutical Industry's EBIT is ₪18.1M making its interest coverage ratio 2.7. It has cash and short-term investments of ₪5.4M.
Key information
55.6%
Debt to equity ratio
₪93.97m
Debt
| Interest coverage ratio | 2.7x |
| Cash | ₪5.45m |
| Equity | ₪169.15m |
| Total liabilities | ₪282.68m |
| Total assets | ₪451.83m |
Recent financial health updates
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Recent updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30Financial Position Analysis
Short Term Liabilities: REKA's short term assets (₪225.0M) exceed its short term liabilities (₪151.0M).
Long Term Liabilities: REKA's short term assets (₪225.0M) exceed its long term liabilities (₪131.7M).
Debt to Equity History and Analysis
Debt Level: REKA's net debt to equity ratio (52.3%) is considered high.
Reducing Debt: REKA's debt to equity ratio has reduced from 58.6% to 55.6% over the past 5 years.
Debt Coverage: REKA's debt is well covered by operating cash flow (25.7%).
Interest Coverage: REKA's interest payments on its debt are not well covered by EBIT (2.7x coverage).